Deals: Page 7
-
Getty Images
Taiho buys Swiss biotech and its ADC tech for $400M
The pharma will acquire Araris Biotech to gain access to three preclinical ADCs and a linking technology Araris claims is superior to existing platforms.
By Delilah Alvarado • March 17, 2025 -
Christopher Furlong via Getty Images
AstraZeneca adds ‘in vivo’ cell therapy capabilities with EsoBiotech deal
The pharma is paying up to $1 billion to buy the Belgian startup, whose technology it sees as useful in treating cancer and autoimmune conditions.
By Ben Fidler • March 17, 2025 -
Getty Images
MeiraGTx spins Parkinson’s, obesity gene therapies into AI startup
The joint venture with generative AI firm Hologen hands MeiraGTx $200 million up front as well as other financial perks — a “transformative” deal, according to the company’s CEO.
By Jacob Bell • March 13, 2025 -
Elizabeth Regan/BioPharma Dive
Mallinckrodt, Endo to combine in $7B deal
The merger will give the combined entity the financial flexibility to pursue drug licensing deals and broaden its therapeutic focus, executives said on a conference call.
By Kristin Jensen • March 13, 2025 -
Permission granted by Roche
Obesity drugsRoche broadens obesity drug plans with $1.65B Zealand deal
The deal gives the Swiss pharma access to an experimental amylin-targeting treatment it will test in combination with drugs it acquired from Carmot.
By Jonathan Gardner • March 12, 2025 -
Courtesy of CordenPharma
Viking inks CordenPharma deal to boost obesity drug supply
The biotech will commit $150 million to an alliance that hands it significant production capacity for a closely watched weight loss treatment.
By Jonathan Gardner • March 11, 2025 -
Getty Images
2seventy bio, Bluebird’s cell therapy spinout, sells to Bristol Myers for less than $300M
The deal ends 2Seventy’s short run as an independent company, during which it restructured, sold off research and lost nearly all of its market value.
By Ben Fidler • March 11, 2025 -
Jacob Bell/BioPharma Dive
Jazz expands in oncology with $935M deal for Chimerix
Chimerix is currently awaiting an FDA decision on accelerated approval of a drug it’s developing for a type of glioma.
By Jonathan Gardner • March 5, 2025 -
Courtesy of AbbVie
Obesity drugsAbbVie gets into obesity with $350M deal for once-weekly shot
A licensing deal with Denmark’s Gubra gives the immunology giant control of an experimental therapy that could compete with drugs from Novo Nordisk, Eli Lilly and Zealand.
By Jonathan Gardner • March 3, 2025 -
Christopher Furlong via Getty Images
AstraZeneca deepens China presence with FibroGen deal
The $160 million acquisition of a FibroGen subsidiary expands AstraZeneca’s foothold in China while the company works through government investigations into its business practices there.
By Kristin Jensen • Feb. 20, 2025 -
Getty Images
Trump administrationFTC retains stricter merger guidelines under Trump
Agency chair Andrew Ferguson sent a memo to staff on Tuesday clarifying that Biden-era guidelines will remain in place — for now.
By Rebecca Pifer Parduhn • Feb. 19, 2025 -
Permission granted by Stoke
Biogen buys rights to Stoke’s rare epilepsy drug
In exchange for $165 million, Biogen now has access to zorevunersen, a potential first-of-its-kind treatment for Dravet syndrome.
By Jacob Bell • Feb. 18, 2025 -
Getty Images
Novartis pays $925M to reel in a startup it helped launch
The acquisition of Anthos Therapeutics could be worth up to $3.1 billion and returns to Novartis a blood thinner it licensed to the Blackstone-backed startup six years ago.
By Ben Fidler • Feb. 11, 2025 -
Getty Images
Deep Dive // China competition‘The bar has risen’: China’s biotech gains push US companies to adapt
Pharma dealmaking for drugs invented in China is putting pressure on U.S. biotechs to compete harder, according to investors and executives interviewed by BioPharma Dive earlier this year.
By Ben Fidler • Jan. 16, 2025 -
Permission granted by Roche
Q&ARoche’s new deals head tries to navigate a more ‘complicated’ and ‘expensive’ biotech world
Roche's core research spans five large areas. Boris Zaïtra, who now leads corporate business development, is confident his team of dealmakers can juggle them.
By Jacob Bell • Jan. 16, 2025 -
Jacob Bell/BioPharma Dive
At JPM, Biogen CEO tries to take down the deal temperature
While Biogen has made an opportunistic bid for partner Sage, its top executive seemed to play down the urgency for his company to go after larger deals.
By Jacob Bell • Jan. 15, 2025 -
Permission granted by Biogen
Brain drug revivalBiogen’s ‘cold and calculated’ offer to buy Sage receives a mixed reaction on Wall Street
Analysts say the deal, which would give Biogen full control over the drug Zurzuvae, could be a smart financial move. Yet it's also unlikely to appease broader investor concerns.
By Jacob Bell • Jan. 13, 2025 -
Getty Images
Lilly pads cancer drug pipeline with Scorpion deal
The pharma will spend up to $2.5 billion to acquire an experimental PI3K inhibitor from Scorpion, which will spin out a new company holding its employees and other assets.
By Ben Fidler • Jan. 13, 2025 -
Mario Tama via Getty Images
Brain drug revivalJ&J to buy psychiatric drug developer Intra-Cellular for $14.6B
Intra-Cellular has had success selling Caplyta, a brain-rebalancing drug that's approved to treat schizophrenia and bipolar depression.
By Ned Pagliarulo , Jacob Bell • Updated Jan. 13, 2025 -
Kena Betancur via Getty Images
Merck moves into obesity with deal for Hansoh’s GLP-1 pill
News of Merck’s licensing of Hansoh’s preclinical medicine pressured shares in Viking and other obesity drug developers seen as likely buyout targets.
By Jonathan Gardner • Dec. 18, 2024 -
Getty Images
Novo Holdings’ purchase of Catalent set to close after regulators’ green light
The $16.5 billion take-private deal can now be completed, along with Novo Nordisk’s related acquisition of three Catalent drug manufacturing plants.
By Ned Pagliarulo • Dec. 16, 2024 -
Courtesy of AbbVie
AbbVie to acquire Roche spinout Nimble in immune drug deal
The pharma will pay $200 million to buy Nimble and a preclinical oral drug that blocks a protein known as IL-23 — the target of AbbVie’s injection Skyrizi.
By Ned Pagliarulo • Dec. 13, 2024 -
Courtesy of GSK
GSK taps a startup for shot at Alzheimer’s drug
The collaboration deal, which could be worth hundreds of millions of dollars, is a “pivotal moment” for Muna Therapeutics, a startup that launched less than four years ago.
By Jacob Bell • Dec. 5, 2024 -
Getty Images
ALS drug developmentDewpoint, Mitsubishi partner on ALS drug in deal worth up to $480M
The collaboration is another vote of confidence in Dewpoint’s biomolecular condensates research, which had already attracted interest from the likes of Bayer and Novo Nordisk.
By Jacob Bell • Dec. 4, 2024 -
Getty Images
Coherus, sharpening immuno-oncology focus, sells another biosimilar for over $500M
The company reached a deal to divest its third biosimilar this year, selling a copycat version of Amgen’s Neulasta for up to $558 million.
By Delilah Alvarado • Dec. 3, 2024
Previous
